Latest News and Press Releases

Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 monthsTop-line results from confirmatory Phase III study with...

Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months Worldwide sales of Crohn’s disease therapies are estimated to...

Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to...

TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

TEL-AVIV, Israel and RALEIGH, N.C., April 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

TEL-AVIV, Israel and RALEIGH, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

TEL-AVIV, Israel and RALEIGH, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

TEL-AVIV, Israel and RALEIGH, N.C., March 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...

Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential...

Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori...